Shaperon Registers Global Patent for Atopic Dermatitis Treatment 'NuGel' Composition... "Accelerating Commercialization with Long-Term Exclusivity"

On November 21, Shaperon announced that the core composition patent for its atopic dermatitis treatment, NuGel, has been registered in Australia. With the acquisition of this patent, the global commercialization potential of NuGel has been significantly enhanced, and the patent expiration has been extended to 2042, securing long-term exclusive rights.

This patent covers the gel formulation technology that includes the GPCR19 agonist HY209, hyaluronic acid, and polysorbate. The technology has been applied to the treatment currently undergoing Phase 2 clinical trials with the U.S. Food and Drug Administration (FDA). NuGel demonstrated both safety and efficacy in Phase 2 Part 1, and Part 2 of the trial is currently underway.

NuGel has significantly fewer side effects compared to existing steroid and immunosuppressive topical agents. It has shown excellent efficacy in patients with mild to moderate symptoms who require long-term management, providing a differentiated competitive edge. Both the Phase 2b Part 1 clinical trial conducted under FDA approval and preclinical animal model studies have proven its high safety and outstanding therapeutic effect.

Shaperon plans to use this Australian patent as a starting point to file patent applications in other major global markets, including the United States, South Korea, Europe, Japan, China, and Canada, in order to secure sufficient patent terms for future technology licensing and commercialization negotiations. The company explained that this patent will not only enable exclusive entry into the Australian market but will also serve as a key asset demonstrating strong commercial potential during global technology transfer negotiations.

A Shaperon representative stated, "NuGel addresses the limitations of existing biological formulations and will offer a practical alternative for patients with mild to moderate symptoms who require long-term management. We will actively expand global commercialization and technology licensing negotiations based on our clinical data and patent assets."

This content was produced with the assistance of AI translation services.